12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Stivarga regorafenib regulatory update

FDA approved Stivarga regorafenib from Bayer to treat previously treated metastatic colorectal cancer (mCRC) a month ahead of the product's Oct. 27 PDUFA date. Onyx has co-promotion rights in the U.S. to the dual acting signal transduction (DAST) inhibitor of multiple kinases and is eligible for a 20%...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >